MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic

Murepavadin is in development as a precision antibiotic to treat chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. It is an outer membrane protein targeting antibiotic– a novel class of antibiotics.

PharmaTimes